Please assess the completion status of the following clinical trial:

Trial Title: Safety and Pharmacokinetics of AT-007 in Healthy Subjects and in Adult Subjects With Classic Galactosemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Classic Galactosemia confirmed by evidence of absent or significantly decreased (\<1%) GALT activity in red blood cells and by GALT gene analysis~* Urine galactitol \>100 mmol/mol creatinine~* Galactose-restricted diet~Exclusion Criteria:~* Complications of CG resulting in disability that, in the opinion of the Investigator, may prevent the subject from completing all study requirements (e.g., severe neurological deficits, severe cognitive impairment, or severe language difficulty).~* Renal disease (eGFR \< 90 mL/min/1.73 m2 or albuminuria).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- AT-007 (Type: EXPERIMENTAL): AT-007 is a CNS and retina penetrant aldose reductase inhibitor.
- Placebo Comparator (Type: PLACEBO_COMPARATOR): Placebo is used as a comparator to the experimental arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).